

PCT/US2003/037157













FIGURE 1



















PCT/US2003/037157

FIGURE 7A









FIGURE 7B

















FIGURE 10A




### FIGURE 10B







WO 2004/047734

12/23












FIGURE 12






A124 HS VP16-MBP
A137 PLP 139-151
A142 PLP 139-151
A15 KBP89-101 91Ala
A2 FLP 139-151
A303 PLP 210-229
A318 NOS 35-55
A319 Filaggrin E128
A326 PLP 139-151
A343 CMFagg 356-388
A371 hMDG 75-87
A372 hMBP 6-14
A374 hMBP 13-21
A406 rat NCC 61-78
A419 rat MBC 72-84
A60 NBP 24-37
A603 CMFagg 356-373
A606 CMFagg 374-388
A607 PLF 139-151 BIOTIM
A63 NBP 87-98
A616 E1 FLP 139-151 BIOTIM
A63 NBP 87-98
A616 E1 FLP 139-151 BIOTIM
A63 NBP 87-98
A616 B1 FLP 139-151 BIOTIM
A64 NOS 35-55 F
A657 abCryg 16-35
A670 abCryg 121-140
A78 hNEF 71-89
A828 15-29 576
A83 hNEF 11-129
A820 LDVM 1-9
A828 15-29 576
A83 hNEF 121-133
A844 120-134 176
A854 hNEF 121-159
A656 NOS 01-22
A660 NOS 01-22
A660 NOS 050 pd72
A87 NEP 85-99
A86 GAInca Cig NBF protein
A910 CFF Cyc Ala-12
A919 CCF cyc Ala-1
A94 NOUG NBF 1-31


# **FIGURE 14A**



### FIGURE 14B





#### FIGURE 15A




#### **FIGURE 15B**

#### % Diabetic at Week 29







# **FIGURE 17A**




# FIGURE 17B


#### 27 Days Post Boost Disease Incidence







20/23









# PCT/US2003/037157

# FIGURE 20A






FIGURE 20B

Day 21 Post Boost Disease Incidence








FIGURE 22